BioSpace News Archive

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to provide additional information on its interim data report for the Phase 2b part of the Company’s Phase 2b/3 clinical study of Ifenprodil for COVID-19.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced today the start of a precision medicine collaboration in schizophrenia (SCZ) with researchers from Columbia University in New York, Dr. Joseph Gogos, Dr. Sander Markx and Dr. Jeffrey Lieberman.

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces the official launch of its flagship program, BEAT®diabetes, and the availability of its proprietary non-invasive, daily-wear adhesive glucose monitor, proBEAT™. The program is supported w

On behalf of the National Kidney Foundation and the American Society of Nephrology, we thank the trainees, clinicians, and the public—particularly people with kidney diseases, kidney failure, and kidney transplants—for their ongoing support of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases.

Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to SIG-005 for the treatment of mucopolysaccharidosis type I (MPS-1), a chronic, progressive lysosomal storage disease.

TheraCell Inc., a leading allograft solution company, today announced that over 25,000 of its licensed demineralized bone fiber products have been delivered by its licensee partners. TheraCell’s partners have seen steady double-digi

Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced a collaboration and research agreement with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Kennedy Krieger Institute.

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that its pivotal Phase 3 trial, ‘EVOGUARD,’ of EVO100 for the prevention of chlamydia and gonorrhea remains firmly on schedule

PROCEPT® BioRobotics Corporation, a surgical robotics company developing intelligent solutions to transform the field of urology, today announced the appointment of Taylor Harris to the company’s Board of Directors.

The new open label part will enroll a total of approximately 150 patients drawn from both current ARMOR patients and newly recruited patients.